This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Top Stocks to Buy on Blockbuster Jobs Data
by Zacks Equity Research
U.S. non-farm payroll data for November shows that job creation hasn't slowed but has shown signs of reacceleration. Here are five stocks from the best-performing sectors.
Ensign Group (ENSG) on Buyout Binge to Boost Capabilities
by Zacks Equity Research
Ensign Group's (ENSG) acquisition spree in Texas and Arizona will enhance its portfolio and better serve the local communities.
Here's Why Should You Hold MEDNAX (MD) in Your Portfolio
by Zacks Equity Research
Riding high on its solid top line as well as strategic buyouts, MEDNAX (MD) holds enough potential to generate returns for investors.
Why Should You Hold Centene (CNC) Stock in Your Portfolio?
by Zacks Equity Research
Acquisitions, rising revenues, growing membership and solid capital position carve out a long-term growth story for Centene (CNC).
Magellan Health's PBM Division Unveils Care Management Plan
by Zacks Equity Research
Magellan Health's (MGLN) pharmacy benefit management division's newly-launched plan is expected to drive value-added healthcare.
Humana, Epione Tie Up to Aid Medicare Advantage Members
by Zacks Equity Research
Humana (HUM) inks deal with Epione Health of Oklahoma to provide better patient care.
Why is HCA Healthcare an Attractive Stock for Your Portfolio?
by Zacks Equity Research
Growing revenues and a strong capital position bode well for HCA Healthcare (HCA).
Why Should You Hold Universal Health in Your Portfolio?
by Zacks Equity Research
Banking on its growing top line and strong segments, Universal Health (UHS) holds potential to reap benefits for investors.
Humana (HUM) to Boost Medicare Advantage Network in Hawaii
by Zacks Equity Research
Humana (HUM) teams up with Hawaii Senior Medical Group to enrich patient experience of Medicare Advantage members in the region.
Humana (HUM) Scales New 52-Week High on Solid Q3 Earnings
by Zacks Equity Research
Humana (HUM) reaches a 52-week high, backed by strong-third-quarter results and Medicare business.
Top Ranked Momentum Stocks to Buy for November 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 12th
Genesis Healthcare's (GEN) Q3 Earnings Beat, Improve Y/Y
by Zacks Equity Research
Genesis Healthcare's (GEN) third-quarter results reflect same store occupancy growth, partly offset by lower revenues.
Genesis Healthcare (GEN) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
Genesis Healthcare's (GEN) third-quarter results are likely to reflect weak revenues, partially offset by same store facility growth and lower expenses.
Genesis Healthcare (GEN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Genesis Healthcare (GEN) closed at $1.28, marking a -0.78% move from the previous day.
Is Genesis Healthcare (GEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GEN) Outperforming Other Medical Stocks This Year?
Genesis Healthcare (GEN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Genesis Healthcare (GEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Genesis Healthcare (GEN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Genesis Healthcare (GEN) closed at $1.38, marking a +0.01% move from the previous day.
The Zacks Analyst Blog Highlights: MDU Resources, AquaVenture, Tenet Healthcare, US Foods and Genesis Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MDU Resources, AquaVenture, Tenet Healthcare, US Foods and Genesis Healthcare
5 Safe Stocks to Counter IMF's Dull Global Economic Outlook
by Zacks Equity Research
Global economy is slowing down and IMF has turned pessimistic. This is the perfect time for investors to go defensive and invest in these five stocks.
Genesis Healthcare (GEN) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Genesis Healthcare (GEN) closed the most recent trading day at $1.52, making no change from the previous trading session.
The Zacks Analyst Blog Highlights: NRG Energy, Lannett Company, Genesis Healthcare, US Foods and Grocery Outlet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NRG Energy, Lannett Company, Genesis Healthcare, US Foods and Grocery Outlet
Buy These 5 Defensive Stocks to Counter Market Volatility
by Zacks Equity Research
Markets have turned volatile due to poor economic data and geopolitical tensions, here are five defensive stocks to boost your portfolio.
Nursing Industry Outlook Buoyant on Increasing Life Expectancy
by Sapna Bagaria
Aging baby boomer population, need for low-cost care facilities and consolidation should aid the growth of the nursing industry.
Is Genesis Healthcare (GEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GEN) Outperforming Other Medical Stocks This Year?
Genesis Healthcare (GEN) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Genesis Healthcare (GEN) closed at $1.17, marking no change from the previous day.